Nasus Pharma Ltd.
AMEX: NSRX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- New York Stock Exchange American
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dan Teleman
- Employees
- 2
- Headquarters
- Tel Aviv, Israel
- IPO year
- 2025
- Market cap
- $26.4M
- Website
- http://www.nasuspharma.com
Loading NSRX…
Loading profile data…Frequently asked questions about NSRX
What does Nasus Pharma Ltd. (NSRX) do?
Nasus Pharma Ltd. is a specialized pharmaceutical firm currently advancing through clinical trials. Their primary focus is on developing innovative nasal medications designed to swiftly address critical emergency health situations. These urgent conditions include severe allergic reactions, such as anaphylaxis, and instances of opioid overdose. A...
Where does NSRX trade?
Nasus Pharma Ltd. (NSRX) trades on the New York Stock Exchange American.
What sector is NSRX in?
Nasus Pharma Ltd. (NSRX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Nasus Pharma Ltd.?
Dan Teleman is the chief executive officer of Nasus Pharma Ltd. (NSRX).
Where is Nasus Pharma Ltd. headquartered?
Nasus Pharma Ltd. is headquartered in Israel.
Does NSRX pay a dividend?
Nasus Pharma Ltd. (NSRX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did NSRX go public?
Nasus Pharma Ltd. (NSRX) completed its initial public offering in 2025.